Faron Pharmaceuticals hits bump in road for Traumakine manufacturing

Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Wednesday that, further to its update in its interim results in relation to the active pharmaceutical ingredient (API) manufacturing process for ‘Traumakine’, Rentschler Biopharma has sent Faron a letter in which it terminated the agreement concerning the API manufacturing.

The AIM-traded firm said it understood that related to the fact that “significant” upgrading of the API manufacturing process would be required prior to MAA/BLA approval for Traumakine.

“The company is exploring various options for future API manufacturing,” the board said in its statement.

“This termination has no impact on the currently on-going clinical advice process with FDA/EMA, which focuses on the structure of the next Traumakine clinical study.”